Evidence map›Paper›PMID 30966304›Full record

ArticlePolymers2018

Hyperthermia-Triggered Gemcitabine Release from Polymer-Coated Magnetite Nanoparticles.

G R Iglesias, Felisa Reyes-Ortega, B L Checa Fernandez, Ángel V Delgado

Open access · goldAbstract read
In one paragraph

Article in Polymers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

G R IglesiasDepartment of Applied Physics, Facultad de Ciencias, Campus Fuentenueva, School of Sciences, and MNAT Unit of Excellence, University of Granada, 18071 Granada, Spain. iglesias@ugr.es.ORCID 0000-0002-5623-1516
Felisa Reyes-OrtegaDepartment of Applied Physics, Facultad de Ciencias, Campus Fuentenueva, School of Sciences, and MNAT Unit of Excellence, University of Granada, 18071 Granada, Spain. felisareyes@ugr.es.ORCID 0000-0003-2102-7432
B L Checa FernandezDepartment of Applied Physics, Facultad de Ciencias, Campus Fuentenueva, School of Sciences, and MNAT Unit of Excellence, University of Granada, 18071 Granada, Spain. lunachecaf@gmail.com.ORCID 0000-0002-6679-0987
Ángel V DelgadoDepartment of Applied Physics, Facultad de Ciencias, Campus Fuentenueva, School of Sciences, and MNAT Unit of Excellence, University of Granada, 18071 Granada, Spain. adelgado@ugr.es.ORCID 0000-0003-1843-5750
Universidad de Granada · ES

Funding

Feder Funds UEJunta de Andalucía PE2012-FQM694MINECO Ramón y Cajal programme RYC-2014-16901
6 · The paper itself

Abstract

In this work a combined, multifunctional platform, which was devised for the simultaneous application of magnetic hyperthermia and the delivery of the antitumor drug gemcitabine, is described and tested in vitro. The system consists of magnetite particles embedded in a polymer envelope, designed to make them biocompatible, thanks to the presence of poly (ethylene glycol) in the polymer shell. The commercial particles, after thorough cleaning, are provided with carboxyl terminal groups, so that at physiological pH they present negative surface charge. This was proved by electrophoresis, and makes it possible to electrostatically adsorb gemcitabine hydrochloride, which is the active drug of the resulting nanostructure. Both electrophoresis and infrared spectroscopy are used to confirm the adsorption of the drug. The gemcitabine-loaded particles are tested regarding their ability to release it while heating the surroundings by magnetic hyperthermia, in principle their chances as antitumor agents. The release, with first-order kinetics, is found to be faster when carried out in a thermostated bath at 43 °C than at 37 °C, as expected. But, the main result of this investigation is that while the particles retain their hyperthermia response, with reasonably high heating power, they release the drug faster and with zeroth-order kinetics when they are maintained at 43 °C under the action of the alternating magnetic field used for hyperthermia.

Indexed as

biocompatible polymerdrug deliverygemcitabinemagnetic hyperthermiamagnetic nanoparticles

Identifiers

PMID30966304
PMCPMC6415114
OpenAlexW2794263726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.